authID (NasdaqCM:AUID) Q4 2025 Earnings call March 31, 2026 05:00 PM ET Speaker2day, and thank you for standing by. Welcome to the authID Q4 and full year 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. If you would like to remove yo ...

Financial Data and Key Metrics Changes - Venu's total assets grew to $370 million as of December 31, 2025, up $192 million or 108% from $178 million at December 31, 2024 [22] - Property and equipment increased to $305 million as of December 31, 2025, up 123% from $137 million at December 31, 2024 [22] - Total revenue was $17 million for the full year ended December 31, 2025, compared to $17.8 million for the full year ended December 31, 2024 [23] Business Line Data and Key Metrics Changes - Luxe FireSuite and Aikman Club sales reached $126 million for the full year ended December 31, 2025, representing a 62% increase over the $77 million generated in fiscal year 2024 [23] - The triple-net model launched mid-year 2025 accounted for approximately 25% of total fire suite sales for the year [23] Market Data and Key Metrics Changes - Amphitheater revenue grew 94% year-over-year due to a full season in 2025 compared to a partial season in 2024 [10] - The Ford Amphitheatre was named to Billboard's 2026 Top Music Venues list, enhancing its market recognition [10] Company Strategy and Development Direction - The company is focused on building partnerships with world-class operators and expanding its venue portfolio, targeting a total of 40 locations [17][36] - Venu is pursuing a more than just music strategy, including residencies and AI-driven programming to maximize revenue-generating capabilities [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting a strong demand for venues and a robust booking pipeline for the upcoming season [48][50] - The company is actively addressing operational challenges and refining its focus on high-potential venues [14] Other Important Information - Venu completed a $14 million sale-leaseback of its Colorado Springs parking property in Q4 2025, generating a development profit of $6.6 million [24] - The company has formed significant partnerships with brands like PepsiCo and Aramark, indicating strong market validation [17][20] Q&A Session Summary Question: Strategy to attract more institutional investors - Management acknowledged frustration with stock performance and outlined plans to enhance investor relations and attract more institutional investors [28][30] Question: Future market expansion plans - Management detailed ongoing negotiations in 13 markets and plans for strategic expansion in Colorado and Texas [36] Question: Clarification on asset valuation discrepancies - Management explained the gap between the balance sheet value and the appraised value of $1.24 billion, attributing it to municipality-contributed real estate being recorded at zero cost basis [40][43] Question: Outlook for event supply and bookings - Management indicated a strong uptick in bookings and demand for amphitheater events compared to the previous year, with expectations for a robust season ahead [48][50]

Venu (NYSEAM:VENU) Q4 2025 Earnings call March 31, 2026 04:30 PM ET Company ParticipantsHeather Atkinson - CFOJ.W. Roth - Founder, Chairman, and CEOJake Perlmutter - VP of Brand Partnerships, New Era Media, and MarketingJamie Gronowski - Advisory PartnerMarty Calvert - SVP and Financial AdvisorRobert Mudd - SVP of Construction and Market ExpansionTerri Liebler - President of Growth and StrategyVic Sutter - COOWill Hodgson - PresidentConference Call ParticipantsSteven Vasek - AnalystOperatorLadies and gentle ...

ORIC Pharmaceuticals Conference Call Summary Company Overview - **Company**: ORIC Pharmaceuticals (NasdaqGS:ORIC) - **Focus**: Development of rinzimetostat, a PRC2 inhibitor for prostate cancer, and enozertinib, an EGFR inhibitor for non-small cell lung cancer, in collaboration with Bayer and Johnson & Johnson [4][6] Key Points and Arguments Clinical Data and Pipeline - **Rinzimetostat**: A next-generation PRC2 inhibitor designed for superior potency and a 20-hour clinical half-life, minimizing toxicity [5] - **Phase III Trial**: The first phase III trial, named Himalayas-1, will target post-abiraterone metastatic CRPC, a market worth $3.5 billion annually in the U.S. [6][10] - **Efficacy**: Rinzimetostat shows competitive efficacy with early landmark radiographic progression-free survival (RPFS) rates and a favorable safety profile compared to existing therapies [5][8][10] Competitive Landscape - **Current Therapies**: Existing treatments like enzalutamide and docetaxel show median RPFS of 6-9 months, while rinzimetostat aims for a double-digit RPFS [6][7] - **Comparison with Meverometostat**: Rinzimetostat's early data suggests it may outperform meverometostat in terms of safety and efficacy, with a cleaner safety profile [7][9][36] Safety Profile - **Adverse Events**: Most adverse events for rinzimetostat in combination with darolutamide are grade 1 or 2, with a significantly lower incidence of severe events compared to competitors [9][25][36] - **Patient Population**: The trial population is more heavily pretreated than competitors, with a median baseline PSA of 26 for the 400 mg dose group, indicating a more advanced disease state [24][72] Market Potential - **Addressable Market**: The U.S. market for post-abiraterone mCRPC is estimated at over $3.5 billion, with potential expansion into other prostate cancer indications, increasing the total market to over $10 billion [10][41] - **Physician Insights**: Market research indicates a strong preference for rinzimetostat due to its safety profile, potentially capturing 80% of the PRC2 class market share [49] Future Development - **Additional Trials**: Plans for future phase III trials in other indications, including metastatic castration-sensitive prostate cancer and colorectal cancer, are underway [42][50] - **FDA Engagement**: Regular communication with the FDA is ongoing, with an end-of-phase I meeting planned to finalize the trial design and RP3D selection [65][66] Other Important Content - **Preclinical Data**: Rinzimetostat has shown superior potency in preclinical studies compared to first-generation PRC2 inhibitors, supporting its potential as a best-in-class therapy [11][12] - **Mechanistic Rationale**: The drug's ability to reverse epigenetic reprogramming in prostate cancer cells enhances its therapeutic potential when combined with AR inhibitors [14][15] This summary encapsulates the critical insights from the ORIC Pharmaceuticals conference call, highlighting the company's strategic focus on rinzimetostat and its promising clinical data, competitive positioning, and market potential.

Nano Dimension (NasdaqCM:NNDM) Q4 2025 Earnings call March 31, 2026 04:30 PM ET Company ParticipantsDavid Stehlin - CEOJohn Brenton - CFOParvah Sanaria - Director of Investor RelationsConference Call ParticipantsMoshe Sarsadi - AnalystOperatorAlso, note today's event is being recorded. At this time, I would like to turn the conference call over to Parvah Sanaria, Director of Investor Relations. Please go ahead.Parvah SanariaThank you, and good afternoon, everyone. Welcome to Nano Dimension's fourth quarter ...

Aqua Metals (NasdaqCM:AQMS) Q4 2025 Earnings call March 31, 2026 04:30 PM ET Company ParticipantsDan Scott - Senior Vice President and Investor RelationsEric West - CFOSteve Cotton - President and CEOConference Call ParticipantsMickey Legg - Equity Research Analyst in Electric Vehicle SectorOperatorAs a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Dan Scott. Thank you. You may begin.Dan ScottThank you operator, and thank you everyone for joining us ...

Financial Data and Key Metrics Changes - KULR recorded a net loss of approximately $62 million in 2025, primarily due to one-time and non-cash items, including a $14 million mark-to-market expense related to Bitcoin holdings [4][28] - Total revenue for 2025 was $16.1 million, representing a 51% increase from the previous year, driven mainly by Bitcoin mining and battery research grant dollars [7][28] - Battery platform revenue, which includes product sales and contract services, was $7.3 million in 2025, serving as the baseline for growth in 2026 [7][28] Business Line Data and Key Metrics Changes - Product revenue increased by 39%, while service revenue declined by 50% in 2025, indicating a shift towards a product-focused model [28] - The gross margin for product sales was reported at 1% in 2025, reflecting the challenges of early-stage manufacturing [8][28] - KULR has over 30 active customer development programs across various sectors, including KULR ONE Air, KULR ONE Space, and KULR ONE Guardian [12][19] Market Data and Key Metrics Changes - The KULR ONE Air platform is experiencing the most momentum, with over 20 active customer development agreements and plans to produce over 10,000 battery packs per month by late 2026 [29][34] - KULR has entered a five-year preferred battery supply agreement with Caban Energy, which is expected to contribute to revenue growth in the telecom sector [23][32] - The company is also focusing on AI data center applications, with expectations for revenue opportunities to materialize in 2027 [30][41] Company Strategy and Development Direction - The company's mission for 2026 is to eliminate distractions and focus on building and selling more KULR ONE batteries [6][34] - KULR aims to improve gross margins through automation and increased production volume, with an automated production line planned for the second half of 2026 [9][10] - The strategic focus is on high-growth markets such as autonomous platforms, digital infrastructure, and direct energy systems, which require specialized battery solutions [10][20] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges faced in 2025 but emphasizes a strong foundation for growth in 2026, with a commitment to execution and accountability [4][5] - The demand for high-power battery packs is identified as a significant growth driver, particularly in challenging environments [10][20] - Management expresses confidence in the stability and repeatability of the revenue base, with a diversified customer portfolio and ongoing engagements [37][38] Other Important Information - KULR's partnerships with battery cell manufacturers like Amprius and Molicel are part of a long-term strategy to access advanced battery technology [13] - The company is actively engaged in developing NDAA-compliant battery systems in collaboration with Hylio, which is crucial for government and defense-related applications [17][44] Q&A Session Summary Question: Which markets are seeing the most momentum today? - Management highlighted the KULR ONE Air platform for autonomous systems as the area with the highest momentum, with over 20 active customer agreements and plans for significant production [29] Question: Update on AI data center backup power market? - Management stated that development for the AI data center PBU product began in 2025, with expectations for revenue opportunities in 2027 [30] Question: Status in telecom and energy infrastructure? - Management confirmed that production has commenced with Caban Energy and that they are also exploring battery-as-a-service offerings directly with telecom operators [32] Question: Where is management most focused right now? - The primary focus for 2026 is on the KULR ONE Air platform, which shows the highest growth potential [34] Question: Biggest goals and milestones for 2026? - Management aims for significant growth in KULR ONE Air products, with a baseline target of 10,000 packs per month as automation is implemented [36] Question: Stability and repeatability of KULR ONE platform revenue? - Management indicated that the company is moving towards a more stable and repeatable product sales model in 2026, supported by a broader customer base [37][38] Question: Potential role in space-based AI data centers? - Management noted that while there are opportunities, it is not a primary focus for 2026 [39][40] Question: Revenue contributions from recent partnerships? - Management confirmed that both Hylio and Caban are expected to contribute to revenue in 2026, while AI data center business will be more relevant in 2027 [41]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $87.2 million, aligning with the midpoint of revised guidance, while full-year revenue reached $346.8 million, a 1.4% increase over 2024 [3][4] - Adjusted EBITDA for Q4 was $19.2 million, representing a margin expansion to 22%, up from 20.4% in Q4 2024, while full-year Adjusted EBITDA was $68.7 million, a 23% year-over-year increase [4][18] - Free cash flow for the year was $20 million, an increase of $5 million over 2024, with cash flow from operations rising to $37 million, a 19% increase year-over-year [4][14] Business Line Data and Key Metrics Changes - Financial Health revenue totaled $56.2 million in Q4, a 2% year-over-year increase, while Patient Care revenue was $31 million, reflecting a 6.6% decline primarily due to the sunset of the Centriq product [17][18] - For the full year, Financial Health revenue was $221.7 million, up 2%, while Patient Care revenue was approximately flat at $125.2 million [20][21] - Bookings for Q4 were $19.8 million, up $6 million year-over-year, and total bookings for the year were $82.9 million, a 1% increase compared to the prior year [17][20] Market Data and Key Metrics Changes - The overall sales pipeline value is at its highest in 9 quarters, having increased by 53% since the beginning of Q3, with a notable shift towards larger opportunities [5] - The percentage of recurring deals in the pipeline has risen to over 70%, up from approximately 57% last summer, indicating improved quality of opportunities [5] Company Strategy and Development Direction - The company is engaged in a strategic review process to maximize shareholder value and is not issuing formal guidance, but expects modest revenue growth in 2026 and a 200 basis points improvement in Adjusted EBITDA margins [3][22] - The company is focusing on a comprehensive AI strategy across four pillars: Financial Health, Patient Care, Customer Service, and Internal Development, aiming to enhance operational efficiency and customer satisfaction [8][9] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in customer retention, particularly in the CBO segment, and highlighted ongoing efforts to improve processes and customer experience [6][29] - The company remains optimistic about its growth trajectory, citing a healthy demand environment and confidence in converting its growing pipeline [6][10] Other Important Information - The company has strengthened its financial position through disciplined debt reduction, lowering net debt by approximately $19.5 million year-to-date, and improving its net leverage ratio to 2x [14][15] - The company has opened a new Global Capacity Center in Chennai, which is expected to enhance its global delivery model [7] Q&A Session Summary Question: Can you explain the new bookings metric and how to use it for revenue visibility? - Management confirmed that recurring revenues and assumptions about bookings at conversion are key to understanding revenue visibility [25][26] Question: How did customer retention rates perform in Q4, and what are the expectations for 2026? - Management indicated that retention rates did not improve significantly in Q4, with expectations for modest improvement in 2026 [27][28] Question: What is the timeline for the strategic review process? - Management stated there is no specific timeline for the strategic review, emphasizing the focus on achieving the right outcome for shareholder value [30] Question: How do you see the conversion timing of larger deals in the pipeline? - Management noted that there are no capacity constraints, but the timing of bookings is often dependent on customer readiness [34][35] Question: What are the opportunities from the Rural Health Fund? - Management expressed commitment to helping hospitals access the $50 billion fund and emphasized the importance of being involved in shaping its use [72][74] Question: How is AI impacting the competitive landscape? - Management reported no significant changes in the competitive landscape yet, but acknowledged increased customer inquiries about AI initiatives [76][79] Question: What is the outlook for margin expansion? - Management indicated that the 200 basis points margin expansion will come from a combination of cost optimization and revenue mix improvements [80][81]

Aqua Metals (NasdaqCM:AQMS) Q4 2025 Earnings call March 31, 2026 04:30 PM ET Company ParticipantsDan Scott - Senior Vice President and Investor RelationsEric West - CFOSteve Cotton - President and CEOConference Call ParticipantsMickey Legg - Equity Research Analyst in Electric Vehicle SectorOperatorAs a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Dan Scott. Thank you. You may begin.Dan ScottThank you operator, and thank you everyone for joining us ...

Edible Garden (NasdaqCM:EDBL) Q4 2025 Earnings call March 31, 2026 04:30 PM ET Company ParticipantsJeremy Pearlman - Equity Research AssociateJim Kras - CEOKostas Dafoulas - Interim CFOTed Ayvas - Investor Relations ContactConference Call ParticipantsNone - AnalystOperatorPlease note, this conference is being recorded. I will now turn the conference over to your host, Ted Ayvas, Investor Relations. The floor is yours.Ted AyvasThanks, John. Good afternoon, and thank you for joining Edible Garden's 2025 fourt ...